PHAT Dividend History & Analysis | Yield
PHAT has a dividend yield of and paid per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Pharmaceuticals
| SYMBOL | MARKET CAP USD | YIELD TTM | YIELD ON COST 5y |
|---|---|---|---|
| SAN PA Sanofi |
107,581 M | 5.54% | 5.81% |
| BMY NYSE Bristol-Myers Squibb |
136,004 M | 4.71% | 4.73% |
| NVS NYSE Novartis |
289,023 M | 3.06% | 6.44% |
| GSK NYSE GlaxoSmithKline |
101,783 M | 3.53% | 5.43% |
| TAK NYSE Takeda Pharmaceutical |
57,579 M | 3.92% | 4.55% |
| MRK NYSE Merck |
368,941 M | 3.29% | 5.17% |
| NOVN SW Novartis |
289,994 M | 2.99% | 5.64% |
| VTRS NASDAQ Viatris |
19,400 M | 3.50% | 4.04% |
| ORNBV HE Orion |
12,952 M | 2.56% | 5.68% |
| HLUN-B CO H Lundbeck |
6,415 M | 3.08% | 3.39% |
| SYMBOL | MARKET CAP USD | GROWTH RATE | CONSISTENCY |
|---|---|---|---|
| HLUN-B CO H Lundbeck |
6,415 M | 26.64% | 100.0% |
| SECT-B ST Sectra (publ) |
5,876 M | 19.74% | 99.2% |
| LLY NYSE Eli Lilly |
1,048,777 M | 15.24% | 100.0% |
| NVS NYSE Novartis |
289,023 M | 8.79% | 100.0% |
| MRK NYSE Merck |
368,941 M | 5.41% | 100.0% |
| SAN PA Sanofi |
107,581 M | 5.39% | 100.0% |
| RPRX NASDAQ Royalty Pharma |
35,161 M | 5.31% | 100.0% |
| IPN PA Ipsen |
15,655 M | 7.55% | 98.0% |
| JNJ NYSE Johnson & Johnson |
640,479 M | 4.72% | 100.0% |
| NOVN SW Novartis |
289,994 M | 4.53% | 100.0% |
PHAT Dividend History
Dividend Monthly Return EX date, 0 years of data
Average monthly dividend return by ex-dividend date. The score below shows reliability based on how consistently dividends were paid in that month.
PHAT Dividend FAQ
As of September 2026, PHAT's dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 9.50.
As of September 2026 PHAT does not pay a dividend.
Over the last 12 months, PHAT has issued dividend payments.
Based on historical data, the forecasted dividends per share for PHAT for the next payments are between 0 (+0.0%) and 0 (+0.0%). This suggests the dividend will remain relatively stable. The expected Yield for the next 12 months is about -%.
The next Ex-Dividend date for Phathom Pharmaceuticals (PHAT) is currently unknown.
The next Ex-Dividend date for Phathom Pharmaceuticals (PHAT) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.
PHAT's average dividend growth rate over the past 5 years is -% per year.
PHAT's 5-Year Yield on Cost is -%. If you bought PHAT's shares at 35.41 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.
PHAT Payout Consistency is 0.0%. The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
PHAT's % Dividend Yield is considered as unknown.
The Dividend Payout Ratio of PHAT is unknown.
PHAT's Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.
PHAT Outstanding Shares Analysis
Key Metric Definitions
Annual dividend per share divided by current share price.
Percentage of earnings paid as dividends. Below 60% = safe, above 100% = unsustainable.
Percentage of Free Cash Flow paid as dividends. More reliable than Payout Ratio since it measures actual cash.
Compound annual growth rate of dividends over the last 5 years.
Reliability of dividend payments over lifetime. Penalizes cuts and pauses.
Your effective yield if you bought 5 years ago. Shows dividend growth impact over time.
Consecutive years of dividend payments. 25+ years = Dividend Aristocrat.
Proprietary score (0-100) combining yield, growth, safety and consistency.
Last update: 2026-08-30 02:05 UTC